489 related articles for article (PubMed ID: 17312332)
1. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.
Wright JR; Ung YC; Julian JA; Pritchard KI; Whelan TJ; Smith C; Szechtman B; Roa W; Mulroy L; Rudinskas L; Gagnon B; Okawara GS; Levine MN
J Clin Oncol; 2007 Mar; 25(9):1027-32. PubMed ID: 17312332
[TBL] [Abstract][Full Text] [Related]
2. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.
Witzig TE; Silberstein PT; Loprinzi CL; Sloan JA; Novotny PJ; Mailliard JA; Rowland KM; Alberts SR; Krook JE; Levitt R; Morton RF
J Clin Oncol; 2005 Apr; 23(12):2606-17. PubMed ID: 15452187
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial.
Grote T; Yeilding AL; Castillo R; Butler D; Fishkin E; Henry DH; DeLeo M; Fink K; Sullivan DJ
J Clin Oncol; 2005 Dec; 23(36):9377-86. PubMed ID: 16361638
[TBL] [Abstract][Full Text] [Related]
4. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
Voravud N; Sriuranpong V; Suwanrusme H
J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
[TBL] [Abstract][Full Text] [Related]
5. Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy.
Littlewood TJ; Nortier J; Rapoport B; Pawlicki M; de Wasch G; Vercammen E; Schuette W; Wils J; Freund M;
Hematol Oncol; 2003 Dec; 21(4):169-80. PubMed ID: 14735555
[TBL] [Abstract][Full Text] [Related]
6. Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial.
Engert A; Josting A; Haverkamp H; Villalobos M; Lohri A; Sökler M; Zijlstra J; Sturm I; Topp MS; Rank A; Zenz T; Vogelhuber M; Nogova L; Borchmann P; Fuchs M; Flechtner HH; Diehl V
J Clin Oncol; 2010 May; 28(13):2239-45. PubMed ID: 20368566
[TBL] [Abstract][Full Text] [Related]
7. A new induction schedule of epoetin alfa 40.000 IU in anemic patients with advanced lung cancer.
Ariganello O; Mancuso A; Di Molfetta M; Diana F; Beccaglia P; Cortesi E; De Marinis F
Lung Cancer; 2004 Oct; 46(1):119-24. PubMed ID: 15364140
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
Vincent JL; Spapen HD; Creteur J; Piagnerelli M; Hubloue I; Diltoer M; Roman A; Stevens E; Vercammen E; Beaver JS
Crit Care Med; 2006 Jun; 34(6):1661-7. PubMed ID: 16607233
[TBL] [Abstract][Full Text] [Related]
9. Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: results of a multicenter, Phase III, randomized, double-blind, placebo-controlled study.
Tsuboi M; Ezaki K; Tobinai K; Ohashi Y; Saijo N
Jpn J Clin Oncol; 2009 Mar; 39(3):163-8. PubMed ID: 19164318
[TBL] [Abstract][Full Text] [Related]
10. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.
Leyland-Jones B; Semiglazov V; Pawlicki M; Pienkowski T; Tjulandin S; Manikhas G; Makhson A; Roth A; Dodwell D; Baselga J; Biakhov M; Valuckas K; Voznyi E; Liu X; Vercammen E
J Clin Oncol; 2005 Sep; 23(25):5960-72. PubMed ID: 16087945
[TBL] [Abstract][Full Text] [Related]
11. Early Intervention with epoetin alfa during platinum-based chemotherapy: an analysis of quality-of-life results of a multicenter, randomized, controlled trial compared with population normative data.
Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G
Oncologist; 2006 Feb; 11(2):197-205. PubMed ID: 16476840
[TBL] [Abstract][Full Text] [Related]
12. Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer.
Hoskin PJ; Robinson M; Slevin N; Morgan D; Harrington K; Gaffney C
J Clin Oncol; 2009 Dec; 27(34):5751-6. PubMed ID: 19884550
[TBL] [Abstract][Full Text] [Related]
13. Chronic anemia and fatigue in elderly patients: results of a randomized, double-blind, placebo-controlled, crossover exploratory study with epoetin alfa.
Agnihotri P; Telfer M; Butt Z; Jella A; Cella D; Kozma CM; Ahuja M; Riaz S; Akamah J
J Am Geriatr Soc; 2007 Oct; 55(10):1557-65. PubMed ID: 17697104
[TBL] [Abstract][Full Text] [Related]
14. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
[TBL] [Abstract][Full Text] [Related]
15. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.
Chang J; Couture F; Young S; McWatters KL; Lau CY
J Clin Oncol; 2005 Apr; 23(12):2597-605. PubMed ID: 15452188
[TBL] [Abstract][Full Text] [Related]
16. Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa.
Lefebvre P; Vekeman F; Sarokhan B; Enny C; Provenzano R; Cremieux PY
Curr Med Res Opin; 2006 Oct; 22(10):1929-37. PubMed ID: 17022852
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
[TBL] [Abstract][Full Text] [Related]
18. Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level.
Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G
Oncologist; 2006 Feb; 11(2):206-16. PubMed ID: 16476841
[TBL] [Abstract][Full Text] [Related]
19. Prior red blood cell transfusions in cancer patients increase the risk of subsequent transfusions with or without recombinant human erythropoietin management.
Couture F; Turner AR; Melosky B; Xiu L; Plante RK; Lau CY; Quirt I
Oncologist; 2005 Jan; 10(1):63-71. PubMed ID: 15632253
[TBL] [Abstract][Full Text] [Related]
20. Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer.
Steensma DP; Molina R; Sloan JA; Nikcevich DA; Schaefer PL; Rowland KM; Dentchev T; Novotny PJ; Tschetter LK; Alberts SR; Hogan TF; Law A; Loprinzi CL
J Clin Oncol; 2006 Mar; 24(7):1079-89. PubMed ID: 16505427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]